In patients with multiple classifier endometrial cancer, the presence of POLE mutations is associated with a favorable prognosis, and no recurrences were observed even when MMRd/MSI-H and/or p53 abnormalities coexist (26). This evidence concerns the gene POLE and endometrial cancer.